A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Head and Neck Squamous Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Cervix
- Non Squamous Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Esophagus
- Squamous Cell Carcinoma of the Anus
- Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- InduPro, Inc.
- Last updated on ClinicalTrials.gov
- September 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- START Los Angeles · Los Angeles, CA
Florida · 1
- Florida Cancer Specialists · Sarasota, FL
Indiana · 1
- Community Cancer Center North · Indianapolis, IN
New York · 2
- Roswell Park Cancer Institute · Buffalo, NY
- START New York Long Island · Lake Success, NY
Texas · 1
- START Dallas Forth Worth · Fort Worth, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.